These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

206 related items for PubMed ID: 27411063

  • 61.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 62. Antigenicity and immunogenicity of HIV-1 gp140 with different combinations of glycan mutation and V1/V2 region or V3 crown deletion.
    Fu M, Hu K, Hu H, Ni F, Du T, Shattock RJ, Hu Q.
    Vaccine; 2019 Dec 03; 37(51):7501-7508. PubMed ID: 31564450
    [Abstract] [Full Text] [Related]

  • 63. Optimization of the EC26-2A4 Epitope in the gp41 Membrane Proximal External Region Targeted by Neutralizing Antibodies from an Elite Controller.
    Ringel O, Müller K, Koch J, Brill B, Wolf T, Stephan C, Vieillard V, Debré P, Dietrich U.
    AIDS Res Hum Retroviruses; 2018 Apr 03; 34(4):365-374. PubMed ID: 29262692
    [Abstract] [Full Text] [Related]

  • 64. Enhancing exposure of HIV-1 neutralization epitopes through mutations in gp41.
    Blish CA, Nguyen MA, Overbaugh J.
    PLoS Med; 2008 Jan 03; 5(1):e9. PubMed ID: 18177204
    [Abstract] [Full Text] [Related]

  • 65. Anti-HIV B Cell lines as candidate vaccine biosensors.
    Ota T, Doyle-Cooper C, Cooper AB, Huber M, Falkowska E, Doores KJ, Hangartner L, Le K, Sok D, Jardine J, Lifson J, Wu X, Mascola JR, Poignard P, Binley JM, Chakrabarti BK, Schief WR, Wyatt RT, Burton DR, Nemazee D.
    J Immunol; 2012 Nov 15; 189(10):4816-24. PubMed ID: 23066156
    [Abstract] [Full Text] [Related]

  • 66. Diverse antibody genetic and recognition properties revealed following HIV-1 envelope glycoprotein immunization.
    Phad GE, Vázquez Bernat N, Feng Y, Ingale J, Martinez Murillo PA, O'Dell S, Li Y, Mascola JR, Sundling C, Wyatt RT, Karlsson Hedestam GB.
    J Immunol; 2015 Jun 15; 194(12):5903-14. PubMed ID: 25964491
    [Abstract] [Full Text] [Related]

  • 67. Generation of HIV-1 potent and broad neutralizing antibodies by immunization with postfusion HR1/HR2 complex.
    Dawood R, Benjelloun F, Pin JJ, Kone A, Chanut B, Jospin F, Lucht F, Verrier B, Moog C, Genin C, Paul S.
    AIDS; 2013 Mar 13; 27(5):717-30. PubMed ID: 23719346
    [Abstract] [Full Text] [Related]

  • 68. Specificity of antibodies produced against native or desialylated human immunodeficiency virus type 1 recombinant gp160.
    Benjouad A, Gluckman JC, Montagnier L, Bahraoui E.
    J Virol; 1993 Mar 13; 67(3):1693-7. PubMed ID: 7679751
    [Abstract] [Full Text] [Related]

  • 69. CD4-Induced Antibodies Promote Association of the HIV-1 Envelope Glycoprotein with CD4-Binding Site Antibodies.
    Gardner MR, Fellinger CH, Prasad NR, Zhou AS, Kondur HR, Joshi VR, Quinlan BD, Farzan M.
    J Virol; 2016 Sep 01; 90(17):7822-32. PubMed ID: 27334589
    [Abstract] [Full Text] [Related]

  • 70. Comparative Immunogenicity of Evolved V1V2-Deleted HIV-1 Envelope Glycoprotein Trimers.
    Bontjer I, Melchers M, Tong T, van Montfort T, Eggink D, Montefiori D, Olson WC, Moore JP, Binley JM, Berkhout B, Sanders RW.
    PLoS One; 2013 Sep 01; 8(6):e67484. PubMed ID: 23840716
    [Abstract] [Full Text] [Related]

  • 71. HIV-1 Env-specific memory and germinal center B cells in C57BL/6 mice.
    Soldemo M, Pedersen GK, Karlsson Hedestam GB.
    Viruses; 2014 Sep 05; 6(9):3400-14. PubMed ID: 25198199
    [Abstract] [Full Text] [Related]

  • 72. Early Antibody Lineage Diversification and Independent Limb Maturation Lead to Broad HIV-1 Neutralization Targeting the Env High-Mannose Patch.
    MacLeod DT, Choi NM, Briney B, Garces F, Ver LS, Landais E, Murrell B, Wrin T, Kilembe W, Liang CH, Ramos A, Bian CB, Wickramasinghe L, Kong L, Eren K, Wu CY, Wong CH, IAVI Protocol C Investigators & The IAVI African HIV Research Network, Kosakovsky Pond SL, Wilson IA, Burton DR, Poignard P.
    Immunity; 2016 May 17; 44(5):1215-26. PubMed ID: 27192579
    [Abstract] [Full Text] [Related]

  • 73. Achieving Potent Autologous Neutralizing Antibody Responses against Tier 2 HIV-1 Viruses by Strategic Selection of Envelope Immunogens.
    Hessell AJ, Malherbe DC, Pissani F, McBurney S, Krebs SJ, Gomes M, Pandey S, Sutton WF, Burwitz BJ, Gray M, Robins H, Park BS, Sacha JB, LaBranche CC, Fuller DH, Montefiori DC, Stamatatos L, Sather DN, Haigwood NL.
    J Immunol; 2016 Apr 01; 196(7):3064-78. PubMed ID: 26944928
    [Abstract] [Full Text] [Related]

  • 74. Reduced Potency and Incomplete Neutralization of Broadly Neutralizing Antibodies against Cell-to-Cell Transmission of HIV-1 with Transmitted Founder Envs.
    Li H, Zony C, Chen P, Chen BK.
    J Virol; 2017 May 01; 91(9):. PubMed ID: 28148796
    [Abstract] [Full Text] [Related]

  • 75. Recombinant HIV envelope proteins fail to engage germline versions of anti-CD4bs bNAbs.
    Hoot S, McGuire AT, Cohen KW, Strong RK, Hangartner L, Klein F, Diskin R, Scheid JF, Sather DN, Burton DR, Stamatatos L.
    PLoS Pathog; 2013 Jan 01; 9(1):e1003106. PubMed ID: 23300456
    [Abstract] [Full Text] [Related]

  • 76.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 77. Antigenic implications of human immunodeficiency virus type 1 envelope quaternary structure: oligomer-specific and -sensitive monoclonal antibodies.
    Broder CC, Earl PL, Long D, Abedon ST, Moss B, Doms RW.
    Proc Natl Acad Sci U S A; 1994 Nov 22; 91(24):11699-703. PubMed ID: 7972127
    [Abstract] [Full Text] [Related]

  • 78.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 79.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 80.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.